Pacific Pharm.: license-in of anti-osteoporosis drug.

Published: 2005-11-14 06:59:00

Updated: 2005-11-14 06:59:00

Pacific Pharmaceutical made a license agreement with Gador SA, an Argentina pharmaceutical company, on Oct. 31 for a joint research and licensing of olpadronate, a family of the bisphonphonate, anti-osteoporosis drugs.

Olpadronate was already proved of its efficacy and safety and on the way of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK